Evidence map›Paper›PMID 34185336›Full record

ArticleAmerican journal of hematology2021

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.

Katrin Herzog Tzarfati, Odit Gutwein, Arie Apel, Naomi Rahimi-Levene, Maya Sadovnik, Lotem Harel, Patricia Benveniste-Levkovitz, Adina Bar Chaim, Maya Koren-Michowitz

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 22 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 22 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 22 syntheses or guidelines pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Guideline
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  19. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Pooled it
  20. Pooled it

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Katrin Herzog TzarfatiDepartment of Hematology, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine, Tel Aviv University, Zerifin, Israel.
Odit GutweinDepartment of Hematology, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine, Tel Aviv University, Zerifin, Israel.
Arie ApelDepartment of Hematology, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine, Tel Aviv University, Zerifin, Israel.
Naomi Rahimi-LeveneDepartment of Hematology, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine, Tel Aviv University, Zerifin, Israel.
Maya SadovnikDepartment of Hematology, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine, Tel Aviv University, Zerifin, Israel.
Lotem HarelInternal Department C, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine Tel Aviv University, Zerifin, Israel.
Patricia Benveniste-LevkovitzClinical Chemistry Laboratory, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine Tel Aviv University, Zerifin, Israel.
Adina Bar ChaimClinical Chemistry Laboratory, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine Tel Aviv University, Zerifin, Israel.
Maya Koren-MichowitzDepartment of Hematology, Shamir Medical Center (formerly Assaf Harofe Medical Center), affiliated to Sackler Faculty of Medicine, Tel Aviv University, Zerifin, Israel.ORCID 0000-0002-7223-328X
Tel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with hematologic malignancies have an increased risk of severe COVID-19 infection. Vaccination against COVID-19 is especially important in these patients, but whether they develop an immune response following vaccination is unknown. We studied serologic responses to the BNT162b2 vaccine in this population. A lower proportion of patients were seropositive following vaccination (75%) than in a comparison group (99%; p < 0.001), and median (interquartile range [IQR]) antibody titers in patients were lower (90 [12.4-185.5] and 173 [133-232] AU/ml, respectively; p < 0.001). Older age, higher lactate dehydrogenase, and number of treatment lines correlated with lower seropositivity likelihood and antibody titers, while absolute lymphocyte count, globulin level, and time from last treatment to vaccination correlated with higher seropositivity likelihood and antibody titers. Chronic lymphocytic leukemia patients had the lowest seropositivity rate followed by indolent lymphoma. Patients recently treated with chemo-immunotherapy, anti-CD20 antibodies, BCL2, BTK or JAK2 inhibitors had significantly less seropositive responses and lower median (IQR) antibody titers (29%, 1.9 [1.9-12] AU/ml; 0%, 1.9 [1.9-1.9] AU/ml; 25%, 1.9 [1.9-25] AU/ml; 40%, 1.9 [1.9-92.8] AU/ml; and 42%, 10.9 [5.7-66.4] AU/ml, respectively; p < 0.001). Serological response to BNT162b2 vaccine in patients with hematologic malignancies is considerably impaired, and they could remain at risk for severe COVID-19 infection and death.

Indexed as

AgedAntibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesFemaleHematologic NeoplasmsHumansLeukemia, Lymphocytic, Chronic, B-CellLymphomaMaleMiddle AgedSARS-CoV-2Treatment OutcomeAntibodies, ViralBNT162 VaccineCOVID-19 Vaccines

Identifiers

PMID34185336
PMCPMC8420332
OpenAlexW3175948812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.